Lundbeck Q3 2019 Financial Results slide image

Lundbeck Q3 2019 Financial Results

Eptinezumab demonstrated rapid onset from Day 1 Key secondary endpoint: Percentage reduction on Day 1 I PROMISE-1 PROMISE-2 35% Eptinezumab 100 mg 60% PROMISE 1: -Eptinezumab 300 mg 30% --Placebo 50% Eptinezumab 100 mg Eptinezumab 300 mg -Placebo * Eptinezumab 100mg: 52.3% 25% * Eptinezumab 300mg: 54.9% Placebo: 24.5% Percent of Patients 40% Average 20% baseline % of patients with migraine on any given day: -30% Average baseline % of patients with 30% migraine on any given day: + 15% 10% PROMISE 2: 10% 5% * Eptinezumab 100mg: 50.3% 0% 0% BL Day 1 Wk 1 Wk 2 Wk 3 Wk 4 BL Day 1 Wk 1 Wk 2 Wk 2 Wk 4 -58% 20% 18 Eptinezumab 300mg: 51.6% * Placebo: 27.1% *p=0.0159 vs placebo, unadjusted; +p=0.0312 vs placebo, unadjusted; p<0.0001 vs placebo. 1. Saper J, Wilks K, Chakhava G, et al. Eptinezumab for the Prevention of Episodic Migraine Through 1 Year: Results from the Phase 3 PROMISE-1 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-1) Trial. Presented at: 2019 American Academy of Neurology Annual Meeting: Philadelphia, PA; May 4-10, 2019. $38.003 2. Kudrow D, Lipton R, Silberstein S, et al. Eptinezumab for Prevention of Chronic Migraine: Results of 2 Infusions in the Phase 3 PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) Trial. Presented at: 2019 American Academy of Neurology Annual Meeting: Philadelphia, PA; May 4-10, 2019. P2.10-006 Lundbeck
View entire presentation